Risk signal mining of ixazomib based on the database of FAERS

YANG Li; ZHAO Xincai; XU Rong; ZHANG Jianping

doi:10.6039/j.issn.1001-0408.2023.22.15

您当前的位置：

首页 >

文章列表页 >

Risk signal mining of ixazomib based on the database of FAERS

更新时间：2023-11-25

- Risk signal mining of ixazomib based on the database of FAERS
- ZHONGGUO YAOFANG Vol. 34, Issue 22, Pages: 2770-2774(2023)
- 作者机构：
  
  上海交通大学医学院附属第六人民医院药剂科，上海　200233
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.22.15
  CLC： R969.3;R979.1+9
- Published：30 November 2023，
  
  Received：21 June 2023，
  
  Revised：21 September 2023，
扫描看全文
杨莉,赵新才,徐嵘等.基于美国FAERS的伊沙佐米风险信号挖掘 ^Δ[J].中国药房,2023,34(22):2770-2774.

YANG Li,ZHAO Xincai,XU Rong,et al.Risk signal mining of ixazomib based on the database of FAERS[J].ZHONGGUO YAOFANG,2023,34(22):2770-2774.
杨莉,赵新才,徐嵘等.基于美国FAERS的伊沙佐米风险信号挖掘 ^Δ[J].中国药房,2023,34(22):2770-2774. DOI： 10.6039/j.issn.1001-0408.2023.22.15.

YANG Li,ZHAO Xincai,XU Rong,et al.Risk signal mining of ixazomib based on the database of FAERS[J].ZHONGGUO YAOFANG,2023,34(22):2770-2774. DOI： 10.6039/j.issn.1001-0408.2023.22.15.

摘要

目的

挖掘伊沙佐米的风险信号，为临床合理用药提供参考。

方法

利用Open Vigil 2.1在线工具，提取美国FDA不良事件报告系统（FAERS）数据库中自伊沙佐米在美国上市（2015年11月20日）至Open Vigil网站最近更新（2023年3月31日）的药品不良事件（ADE）报告数据，采用比例失衡法中的报告比值比（PRR）法和贝叶斯置信区间递进神经网络（BCPNN）法进行数据挖掘，采用国际医学用语词典（MedDRA）25.1版对信号的系统器官分类（SOC）和首选术语（PT）进行标准化编码。

结果

共提取到以“伊沙佐米”为“首要怀疑药物”的ADE报告13 841份，涉及患者以男性稍多（49.53%），且年龄多为65岁及以上（72.48%）；报告来自57个国家/地区，以美国（52.90%）为主。共挖掘到阳性信号186个，强、中、弱信号分别有51、99、36个，累及SOC 19个。发生频次和PRR信号强度均排在前50位的PT包括周围神经病（414例，强信号）、血小板计数降低（379例，强信号）、血小板减少症（360例，强信号）、血细胞减少症（75例，强信号）、神经病学症状（41例，强信号），累及SOC为各类神经系统疾病、各类检查和血液及淋巴系统疾病；累及胃肠系统疾病（2 588例）的ADE发生次数最多，包括腹泻（1 077例，强信号）、恶心（737例，中信号）、呕吐（459例，中信号）、便秘（275例，中信号）等；感染及侵染类疾病阳性信号包含PT最多，且多数未被药品说明书记载，其中强信号12个（1 030例）、中信号30个（627例），主要涉及肺部感染、上呼吸道感染、胃肠道感染、脓毒症、带状疱疹等；心脏器官疾病中的心脏淀粉样变性（7例，强信号）、急性冠脉综合征（14例，强信号）和肾脏及泌尿系统疾病中的肾功能损害（91例，中信号）均为较强信号且均未被药品说明书记载。

结论

除需常规关注的伊沙佐米相关胃肠系统疾病、各类神经系统疾病、血液及淋巴系统疾病等常见ADE外，临床还需关注患者在治疗期间可能出现的各种感染，密切监测其心血管毒性和肾功能损害的发生。

Abstract

OBJECTIVE

To explore the risk signal of ixazomib and provide a reference for clinically rational drug use.

METHODS

The Open Vigil 2.1 online tool was used to extract the data of adverse drug events （ADE） reported by the database of FDA adverse event reporting system （FAERS） from the launch of ixazomib in America （November 20th， 2015） to the latest update of the Open Vigil website （March 31st， 2023）. The data were mined by using the proportional reporting ratio （PRR） and Bayesian confidence propagation neural network （BCPNN） of the proportional imbalance method. The signals were coded by system organ class （SOC） and preferred term （PT） according to MedDRA v25.1.

RESULTS

A total of 13 841 ADE reports with ixazomib as the “primary subject” were extracted， involving slightly more male patients （49.53%）， and most of them were 65 years old and above （72.48%）； the reports came from 57 countries/regions， mainly America （52.90%）. A total of 186 positive signals were excavated， with 51 high-intensity， 99 medium-intensity， and 36 low-intensity signals， involving 19 SOCs. The top 50 PT in frequency and signal intensity of PRR included neuropathy peripheral （414 cases， high-intensity signal）， platelet count decreased （379 cases， high-intensity signal）， thrombocytopenia （360 cases， high-intensity signal）， cytopenia （75 cases， high-intensity signal） and neurological symptoms （41 cases， high-intensity signal）. SOC involved included nervous system disorders， investigations， and blood and lymphatic system disorders. ADE occurred most frequently in gastrointestinal diseases （2 588 cases）， including diarrhea （1 077 cases， high-intensity signal）， nausea （737 cases， medium-intensity signal）， vomiting （459 cases， medium-intensity signal）， constipation （275 cases， medium-intensity signal）， and so on. The positive signals of infections and infestations contained the largest number of PTs， and most of them were not recorded in the drug instruction， including 12 high-intensity signals （1 030 cases） and 30 medium-intensity signals （627 cases）， which were mainly distributed in lung infection， upper respiratory infection， gastrointestinal infection， sepsis， herpes zoster and so on. The signals of cardiac amyloidosis （7 cases， high-intensity signal） and acute coronary syndrome （14 cases， high-intensity signal） of cardiac disorders and renal dysfunction （91 cases， medium-intensity signal） of renal and urinary disorders were all strong and had not been recorded in the drug instruction.

CONCLUSIONS

In addition to routine attention to the common ADE of ixazomib in gastrointestinal diseases， nervous system disorders and blood and lymphatic system disorders， clinical attention should also be paid to various infections that may occur during the treatment of patients， and the occurrence of cardiovascular toxicity and renal dysfunction should be monitored.

关键词

伊沙佐米不良事件美国FDA不良事件报告系统信号挖掘

Keywords

adverse drug eventFDA adverse event reporting systemsignal mining

references

中国医师协会血液科医师分会，中华医学会血液学分会. 中国多发性骨髓瘤诊治指南：2022年修订 [J]. 中华内科杂志，2022，61（5）：480-487.

Chinese Hematology Association，Chinese Society of Hematology. Guidelines for the diagnosis and management of multiple myeloma in China：2022 revision[J]. Chin J Intern Med，2022，61（5）：480-487.

COWAN A J，GREEN D J，KWOK M，et al. Diagnosis and management of multiple myeloma：a review[J]. JAMA，2022，327（5）：464-477.

李广彬，沈赟，秦艳，等. 伊沙佐米不良反应文献回顾分析[J]. 中国新药杂志，2022，31（9）：925-928.

LI G B，SHEN Y，QIN Y，et al. Literature review and analysis of adverse drug reactions of ixazomib[J]. Chin J N Drugs，2022，31（9）：925-928.

向倩，任诗慧，李晓明. 伊沙佐米治疗多发性骨髓瘤的疗效性与安全性的Meta分析[J]. 临床输血与检验，2023，25（2）：243-249.

XIANG Q，REN S H，LI X M. Efficacy and safety of therapy with ixazomib in patients with multiple myeloma：a meta analysis[J]. J Clin Transfus Lab Med，2023，25（2）：243-249.

KUMAR S，MOREAU P，HARI P，et al. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple mye-loma[J]. Br J Haematol，2017，178（4）：571-582.

KRANTZ M J，RUDO T J，HAIGNEY M C P，et al. Ventricular arrhythmias associated with over-the-counter and recreational opioids[J]. J Am Coll Cardiol，2023，81（23）：2258-2268.

JIAO X F，SONG K P，JIAO X Y，et al. Hyperuricaemia，gout and related adverse events associated with antihypertensive drugs：a real-world analysis using the FDA adverse event reporting system[J]. Front Pharmacol，2023，13：1045561.

LUCK S. Factoring a 2×2 contingency table[J]. PLoS One，2019，14（10）：e0224460.

LAO D H，CHEN Y，FAN J，et al. Assessing taxane-associated adverse events using the FDA adverse event reporting system database[J]. Chin Med J，2021，134（12）：1471-1476.

GUAN Y Y，JI L，ZHENG L，et al. Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions[J]. Front Pharmacol，2022，13：892503.

潘辛梅，马攀. 基于FAERS数据库对玛巴洛沙韦安全警戒信号的挖掘与分析[J]. 中国抗生素杂志，2023，48（4）：466-472.

PAN X M，MA P. Detection and analysis of the safety signals of baloxavir marboxil based on FAERS database[J]. Chin J Antibiot，2023，48（4）：466-472.

FACON T，VENNER C P，BAHLIS N J，et al. Oral ixazomib，lenalidomide，and dexamethasone for transplant-ineligible patients with newly diagnosed multiple mye-loma[J]. Blood，2021，137（26）：3616-3628.

王婧，商京晶，金松，等. 伊沙佐米全口服方案治疗复发难治多发性骨髓瘤的疗效分析[J]. 中华内科杂志，2022，61（1）：95-98.

WANG J，SHANG J J，JIN S，et al. Efficacy of total oral regimens containing ixazomib in patients with relapsed and refractory multiple myeloma[J]. Chin J Intern Med，2022，61（1）：95-98.

杨扬，夏忠军，张文皓，等. 伊沙佐米、来那度胺、地塞米松治疗复发/难治多发性骨髓瘤的疗效与安全性分析：一项国内多中心真实世界研究[J]. 中华血液学杂志，2021，42（8）：628-634.

YANG Y，XIA Z J，ZHANG W H，et al. The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma：a multicenter real-world study in China[J]. Chin J Hematol，2021，42（8）：628-634.

DIMOPOULOS M A，SCHJESVOLD F，DORONIN V，et al. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory，proteasome inhibitor-exposed multiple myeloma：a randomized phase 2 trial[J]. Blood Cancer J，2022，12（1）：9.

GEORGIOPOULOS G，MAKRIS N，LAINA A，et al. Cardiovascular toxicity of proteasome inhibitors：underlying mechanisms and management strategies：JACC：Cardio Oncology state-of-the-art review[J]. JACC CardioOncol，2023，5（1）：1-21.

DIMOPOULOS M A，MERLINI G，BRIDOUX F，et al. Management of multiple myeloma-related renal impairment：recommendations from the International Myeloma Working Group[J]. Lancet Oncol，2023，24（7）：e293-e311.

YUI J C，DISPENZIERI A，LEUNG N. Ixazomib-induced thrombotic microangiopathy[J]. Am J Hematol，2017，92（4）：E53-E55.

ATALLAH-YUNES S A，SOE M H. Drug-induced thrombotic microangiopathy due to cumulative toxicity of ixazomib[J]. Case Rep Hematol，2018，2018：7063145.

NGUYEN M N，NAYERNAMA A，JONES S C，et al. Proteasome inhibitor-associated thrombotic microangiopathy：a review of cases reported to the FDA adverse event reporting system and published in the literature[J]. Am J Hematol，2020，95（9）：E218-E222.

黄玲，王凤玲，陈力，等. 基于美国FAERS数据库的利培酮不良事件信号挖掘与分析[J]. 中国药房，2023，34（3）：350-354.

HUANG L，WANG F L，CHEN L，et al. Mining and analysis of risperidone adverse event signals based on FAERS database[J]. China Pharm，2023，34（3）：350-354.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Signal mining and analysis of adverse drug event signals of darolutamide

Data mining and analysis of oxaliplatin-related adverse events of nervous system

Mining and analysis of lorlatinib-induced adverse drug event signals

Data-mining of Adverse Drug Events Signals for Tocilizumab Based on US FAERS Database

ADR Signal Mining of Rivaroxaban Based on FDA Adverse Event Reporting Database

Related Author

KANG Jian

CHEN Jinhua

QIAO Lijuan

YANG Ping

LIU Ning

KONG Yan

FAN Baoxia

HUANG Mengwen

Related Institution

Dept. of Pharmacy， the First Affiliated Hospital of Zhengzhou University

Dept. of Pharmacy， the Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital

Dept. of Pharmacy， the Fourth People’s Hospital of Jinan

Dept. of Pharmacy， the Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Dept. of Pharmacy， Chengdu Fifth People’s Hospital

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰